Century Therapeutics (IPSC) Research & Development (2020 - 2026)

Century Therapeutics (IPSC) has reported Research & Development for 7 consecutive years, with $17.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Research & Development fell 35.65% year-over-year to $17.1 million; the TTM figure through Mar 2026 stood at $63.7 million (down 42.33% YoY), while the FY2025 annual figure was $95.7 million, down 10.8% from the prior year.
• Research & Development eased to $17.1 million in Q1 2026 per IPSC's latest filing, from $19.7 million in the prior quarter.
• Across five years, Research & Development topped out at $29.4 million in Q4 2024 and bottomed at $12000.0 in Q3 2025.
• Historically, Research & Development has averaged $22.8 million across 5 years, with a median of $24.5 million in 2022.
• Annual changes were most pronounced in 2022 — Research & Development soared 37.87% — and 2025, when it slumped 99.96%.
• Century Therapeutics' Research & Development stood at $25.6 million in 2022, then slipped by 12.86% to $22.3 million in 2023, then surged by 31.75% to $29.4 million in 2024, then slumped by 32.95% to $19.7 million in 2025, then retreated by 13.15% to $17.1 million in 2026.
• Business Quant data shows IPSC's Research & Development at $17.1 million in Q1 2026, $19.7 million in Q4 2025, and $12000.0 in Q3 2025.